Group 1 - The company plans to globally offer 17.6488 million shares, with 1.765 million shares available in Hong Kong and 15.8838 million shares for international sale, along with an over-allotment option of 2.6472 million shares [1] - The subscription period is set from December 12 to December 17, with a maximum offer price of HKD 51.00 per share and an entry fee of approximately HKD 10,302.88 for 200 shares [1] - The total expected fundraising amount is HKD 787 million, with a net amount of HKD 709 million, which will be used for the clinical development and commercialization of core products Pro101-1 and Pro-101-2, enhancing R&D capabilities, and general corporate purposes [1] Group 2 - The company’s main business includes technology services, medical device sales, cosmetics wholesale and retail, and medical research and development [2] - The net profits for the years 2023, 2024, and the first three quarters of 2025 (ending September 30) are projected to be -CNY 105 million, -CNY 212 million, and -CNY 134 million, reflecting year-on-year changes of -22.42%, -101.78%, and 18.06% respectively [2]

Group 1 - The company has initiated its IPO process, with the stock code and listing date yet to be disclosed [1] - The expected fundraising amount is projected to be in the billions of Hong Kong dollars, based on the median price per share [2] - The offering structure includes both Hong Kong and international shares, with specific numbers pending [2] Group 2 - The company has identified cornerstone investors who have committed to a significant amount of subscriptions, calculated based on the proposed share price [2] - The use of proceeds from the fundraising is expected to be allocated to specific purposes, although details are not provided [2] - The underwriting and stabilization will be managed by China International Capital Corporation Hong Kong Securities Limited [2]